What is secretory carcinoma of the breast?
Secretory carcinoma of the breast is a rare, usually slow-growing type of breast cancer. Its name comes from the milky, bubbly material, called secretions, that the tumour cells produce and store inside and around them. It makes up well under 1% of all breast cancers.
It was first described in children, and it was once called juvenile breast carcinoma. It is still the most common type of breast cancer in children and teenagers. However, most people with this cancer are adults, with a median age in the late 40s to mid-50s (Gong et al., 2021; Boustros et al., 2024). It can also affect men.
Most of these tumours carry a specific gene fusion called ETV6::NTRK3. This fusion drives the growth of the cancer and can be targeted with modern tablets called TRK inhibitors if the disease spreads (Mortensen et al., 2021).
How it differs from secretory carcinoma of the salivary gland
A tumour with the same appearance and the same ETV6::NTRK3 fusion also occurs in the salivary glands, described on our page on secretory carcinoma of the salivary gland. The salivary tumour was once called “mammary analogue secretory carcinoma” because it looks so much like the breast version.
| Feature | Secretory carcinoma of the breast | Secretory carcinoma of the salivary gland |
|---|---|---|
| Site | Breast | Parotid and other salivary glands |
| Main treatment | Breast surgery, with radiotherapy for most adults | Removal of the salivary gland |
| Lymph nodes | Armpit nodes | Neck nodes |
| Related care | Managed by a breast team | Managed by a head and neck team |
| Shared feature | ETV6::NTRK3 fusion | ETV6::NTRK3 fusion |
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Rare special type of invasive breast cancer |
| How common | Well under 1% of breast cancers |
| Typical age | Any age from early childhood to old age; median about 48-56 years |
| Sex | Mostly women; men and children also affected |
| Gene change | ETV6::NTRK3 fusion in most cases |
| Hormone receptors | Variable; many are triple-negative or only weakly positive |
| Main treatment | Surgery, usually with radiotherapy in adults |
| Targeted treatment | TRK inhibitors such as larotrectinib and entrectinib for advanced disease |
| Outlook | Generally excellent |
2. Types
By age group
| Group | Features |
|---|---|
| Children and teenagers | Most common breast cancer type in this age group; usually small and very slow-growing |
| Adults | Most cases; outlook still good, but slightly more risk with older age |
| Men | Occasional cases; treated in the same way |
By behaviour
| Type | Description |
|---|---|
| Classic (low-grade) | Mild nuclear changes, few dividing cells |
| High-grade or dedifferentiated | Rare cases with more aggressive features |
3. Causes and risk factors
The cause is not known. The ETV6::NTRK3 fusion arises by chance in the tumour cells and is not inherited.
| Factor | Notes |
|---|---|
| ETV6::NTRK3 fusion | Found in the tumour cells of most cases |
| Age | Can occur at any age |
| Sex | Mainly women |
| Family history | No clear link |
| BRCA1 or BRCA2 | Not specifically linked |
| Hormones | No proven link |
What does the fusion do?
The fusion joins part of the ETV6 gene to part of the NTRK3 gene. The resulting protein keeps a growth signal called TRK switched on all the time, which pushes cells to survive and multiply (Mortensen et al., 2021). The same fusion is found in a few other cancers, including secretory carcinoma of the salivary gland and infantile fibrosarcoma.
Why is it so slow-growing?
Most breast cancers develop through a gradual build-up of many genetic changes. Secretory carcinoma is different: a single fusion gene seems to be enough to start the tumour, and the cancer cells often have few other genetic faults. This simpler genetic make-up may explain why many tumours grow slowly and rarely spread beyond the armpit.
4. How does it look
In the breast
| Finding | Description |
|---|---|
| Lump | A firm, painless, slowly growing lump |
| Location | Often near the nipple in children and young people |
| Size | Usually small; average about 2 cm in a US series |
| Skin and nipple | Usually normal |
On scans
| Scan | Typical findings |
|---|---|
| Mammogram | A rounded or irregular mass, sometimes with calcification; may look harmless |
| Ultrasound | A well-defined or slightly irregular mass |
| MRI | Used if the extent is unclear |
Imaging findings are not specific, and some tumours look like benign lumps (Boustros et al., 2024). A biopsy is therefore needed for any new solid lump.
Under the microscope
| Feature | Description |
|---|---|
| Secretions | Pink, bubbly material inside cells and in spaces between them |
| Growth pattern | Small cysts, solid areas and tube-like structures |
| Nuclei | Mild to moderate changes |
| Dividing cells | Few |
| Stains | S100, mammaglobin, SOX10 and pan-TRK often positive |
| Molecular test | ETV6::NTRK3 fusion by FISH or sequencing |
5. Symptoms
Common symptoms
- A painless lump in the breast
- A lump that grows slowly over months or years
- In children, a lump beneath or near the nipple
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Lump in the armpit | Spread to lymph nodes |
| Nipple discharge | Uncommon |
| Change in breast shape | Larger tumours |
| Cough, breathlessness or abdominal pain | Rare distant spread to the lungs or liver |
Why diagnosis can be delayed
Because the lump is usually painless and grows slowly, people may watch it for months. In young people, doctors may first think of a harmless fibroadenoma. A biopsy settles the question.
When to seek medical advice
See a doctor about any new breast lump, at any age. In children, most breast lumps are harmless, but a lump that keeps growing should be checked. Men should also report breast lumps.
6. Diagnosis
| Step | What is done |
|---|---|
| Examination | Breast and armpit |
| Ultrasound | First test in younger patients |
| Mammogram | For adults |
| Core needle biopsy | Provides tissue for diagnosis |
| Receptor testing | ER, PR and HER2 status |
| Molecular testing | Confirms ETV6::NTRK3 fusion |
| Staging scans | Only if the tumour is large or nodes are involved |
Staging
Secretory carcinoma is staged with the TNM system for breast cancer.
| Stage | Simplified meaning |
|---|---|
| Stage I | Small tumour, no or minimal node spread |
| Stage II | Larger tumour or a few armpit nodes |
| Stage III | Large tumour or extensive node spread |
| Stage IV | Distant spread |
Most people are diagnosed at an early stage. In a US database of 190 patients, about seven in ten had no lymph node spread (Gong et al., 2021).
7. Treatment
Treatment is planned by a breast cancer team, with input from children’s cancer specialists for young patients.
Surgery
| Option | Notes |
|---|---|
| Breast-conserving surgery | Removes the tumour with a margin; preferred where possible |
| Mastectomy | For larger tumours or patient choice |
| Sentinel node biopsy | Checks whether the cancer has reached the armpit nodes |
| Breast-bud preservation | In young girls, surgeons try to protect the developing breast |
In the US database, people who had breast-conserving surgery with radiotherapy had better breast cancer-specific survival than those who had a mastectomy (Gong et al., 2021).
Radiotherapy
| Group | Approach |
|---|---|
| Adults after breast-conserving surgery | Usually recommended |
| Children | Usually avoided because of long-term effects on the growing body |
A narrative review noted that most experts advise radiotherapy for adults but not for children (Min et al., 2022).
Drug treatments
| Treatment | Role |
|---|---|
| Chemotherapy | Uncertain benefit for early disease; considered for high-risk or advanced cases |
| Hormone therapy | Considered when the tumour is hormone receptor-positive |
| TRK inhibitors (larotrectinib, entrectinib) | Approved for NTRK fusion-positive solid tumours that have spread or cannot be removed |
| Clinical trials | For rare advanced cases |
TRK inhibitors have shown high response rates across many cancers with NTRK fusions, including secretory carcinoma (Mortensen et al., 2021).
Why receptor results can be confusing
Secretory carcinomas are often triple-negative, meaning they lack oestrogen and progesterone receptors and HER2. In common breast cancer, triple-negative tumours tend to be aggressive and usually need chemotherapy. Secretory carcinoma is an exception: despite often being triple-negative, it usually behaves gently.
Doctors therefore base treatment on the tumour type and stage, rather than on receptor status alone. Some secretory carcinomas are hormone receptor-positive, and in the US database more than half of those tested were ER-positive (Gong et al., 2021).
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Pain, scarring, change in breast shape, arm swelling after node surgery |
| Radiotherapy | Skin redness, tiredness, breast firmness |
| Hormone therapy | Hot flushes, joint aches |
| TRK inhibitors | Dizziness, weight gain, tiredness, raised liver enzymes |
8. Outlook (prognosis)
Secretory carcinoma generally has an excellent outlook, better than the common no special type breast cancer (Boustros et al., 2024).
| Factor | Effect |
|---|---|
| Age under 20 | Associated with a better outlook |
| Tumour under 2 cm | Associated with a better outlook |
| Three or fewer involved nodes | Associated with a better outlook |
| Older age | Linked to lower breast cancer-specific survival in the US database |
| Distant spread | Rare, but more serious when it happens |
Late recurrences can happen, sometimes many years after surgery, and a few tumours come back early (Mortensen et al., 2021). Long-term follow-up is therefore advised.
9. Follow-up
| Period | Typical checks |
|---|---|
| Years 1-5 | Clinical review every 6-12 months; yearly mammogram for adults |
| After 5 years | Yearly review and imaging as advised |
| Children | Follow-up in a children’s or young adult service, often with ultrasound |
10. Living with secretory carcinoma of the breast
- Attend follow-up, as late recurrences are possible
- Check your breasts and armpits and report changes
- Do arm exercises after node surgery
- Keep active and maintain a healthy weight
- Ask about breast reconstruction if you had a mastectomy
- Seek support from breast cancer charities and young people’s services
Recovery after surgery
| Period | What to expect |
|---|---|
| First days | Mild to moderate pain, wound care, drain if node surgery was done |
| 1-2 weeks | Return to light activities; arm exercises after node surgery |
| 3-6 weeks | Most people return to work and normal routines |
| If radiotherapy follows | Usually starts 4-6 weeks after surgery and lasts 1-3 weeks |
For children and families
A breast cancer diagnosis in a child is very rare and can be shocking for families. Children’s cancer centres can provide play specialists, psychologists and family support. Most children do extremely well, and treatment is planned to protect future breast development as much as possible.
Coping with a rare breast cancer
Most information about breast cancer is written for the common types, so some advice you read may not apply to you. Ask your breast care nurse which parts of general guidance are relevant. Many people find it reassuring to learn that this cancer usually has a very good outlook, while still taking follow-up seriously. Breast cancer charities can offer peer support and practical help.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it only a children’s cancer? | No; most patients are adults |
| Is it inherited? | No; the fusion arises only in the tumour |
| Do I need chemotherapy? | Usually not for small, early tumours |
| What is a TRK inhibitor? | A tablet that blocks the signal from the NTRK fusion; used if the cancer spreads |
| Can men get it? | Yes, rarely |
| Will it affect breastfeeding later? | Surgery on one breast may reduce milk from that side, but the other breast usually works normally |
| Is it the same as the salivary gland tumour? | It shares the same fusion and look, but starts in the breast |
12. Questions to ask your care team
- Has the ETV6::NTRK3 fusion been confirmed?
- What are the hormone receptor and HER2 results?
- Can I have breast-conserving surgery?
- Do I need radiotherapy, chemotherapy or hormone therapy?
- Have my lymph nodes been checked?
- How long will follow-up last?
- If the cancer comes back, could I have a TRK inhibitor?
- Is there a breast care nurse I can contact between appointments?
Resources
- Boustros, P. et al. (2024) ‘Secretory carcinoma of the breast: radiologic-pathologic correlation’, Journal of Breast Imaging, 6(5), pp. 520-528.
- Gong, P. et al. (2021) ‘Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast’, Scientific Reports, 11(1), 14738.
- Min, N. et al. (2022) ‘Advancement of secretory breast carcinoma: a narrative review’, Annals of Translational Medicine, 10(21), 1178.
- Mortensen, L. et al. (2021) ‘Locally recurrent secretory carcinoma of the breast with NTRK3 gene fusion’, The Oncologist, 26(10), pp. 818-824.
- National Cancer Institute (2026) Breast Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.